Erasca Inc

NASDAQ: ERAS
$2.70
+$0.10 (+3.8%)
Closing Price on November 22, 2024

ERAS Stock Chart and Intraday Price

ERAS Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 385.27M USD
Shares Outstanding 151,087,000
Erasca Inc is a trailblazing biopharmaceutical company dedicated to defeating cancer. With a sharp focus on RAS/MAPK pathway-driven cancers, Erasca is advancing a promising pipeline of potential therapies. Its leading candidates, ERAS-007 and ERAS-601, target various cancers including lung, colorectal, and acute myeloid leukemia, as well as advanced solid tumors. Additionally, Erasca is developing ERAS-801 for recurrent brain cancer. Founded in 2018, this San Diego-based company is on a mission to transform cancer treatment.

ERAS Articles

What Has Insiders Eyeing This Biotech Stock
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
Trey Thoelcke
Published: